September 11, 2023
Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress
September 07, 2023
Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program
September 05, 2023
Alkermes to Participate in Two Upcoming Investor Conferences
This year, we’re celebrating 15 years of “Alkermes in Action,” our employee-led volunteer program that supports local non-profit organizations through hands-on activities.
Hear from Craig Hopkinson, M.D. as he reflects on the unmet needs of people living with narcolepsy.
Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.